BioCryst Pharmaceuticals ... (BCRX)
BioCryst Pharmaceuticals Statistics
Share Statistics
BioCryst Pharmaceuticals has 208.96M shares outstanding. The number of shares has increased by 0.48% in one year.
| Shares Outstanding | 208.96M |
| Shares Change (YoY) | 0.48% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 83.34% |
| Shares Floating | 197.13M |
| Failed to Deliver (FTD) Shares | 4.35K |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 17.01M, so 8.21% of the outstanding shares have been sold short.
| Short Interest | 17.01M |
| Short % of Shares Out | 8.21% |
| Short % of Float | 8.71% |
| Short Ratio (days to cover) | 7.86 |
Valuation Ratios
The PE ratio is -17.49 and the forward PE ratio is -124.43. BioCryst Pharmaceuticals's PEG ratio is 0.28.
| PE Ratio | -17.49 |
| Forward PE | -124.43 |
| PS Ratio | 3.45 |
| Forward PS | 2 |
| PB Ratio | -3.27 |
| P/FCF Ratio | -29.88 |
| PEG Ratio | 0.28 |
Enterprise Valuation
BioCryst Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.89B.
| EV / Earnings | -21.24 |
| EV / Sales | 4.19 |
| EV / EBITDA | 147.37 |
| EV / EBIT | -742.25 |
| EV / FCF | -36.28 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of -0.03.
| Current Ratio | 2.63 |
| Quick Ratio | 2.58 |
| Debt / Equity | -0.03 |
| Total Debt / Capitalization | -2.77 |
| Cash Flow / Debt | -4.06 |
| Interest Coverage | -0.03 |
Financial Efficiency
Return on equity (ROE) is 0.19% and return on capital (ROIC) is 0.56%.
| Return on Equity (ROE) | 0.19% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | 0.56% |
| Revenue Per Employee | 777.09K |
| Profits Per Employee | -153.24K |
| Employee Count | 580 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.52 |
Taxes
| Income Tax | 1.93M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by 53.02% in the last 52 weeks. The beta is 1.75, so BioCryst Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.75 |
| 52-Week Price Change | 53.02% |
| 50-Day Moving Average | 8.06 |
| 200-Day Moving Average | 7.5 |
| Relative Strength Index (RSI) | 52.71 |
| Average Volume (20 Days) | 2.59M |
Income Statement
In the last 12 months, BioCryst Pharmaceuticals had revenue of 450.71M and earned -88.88M in profits. Earnings per share was -0.43.
| Revenue | 450.71M |
| Gross Profit | 438.44M |
| Operating Income | -2.54M |
| Net Income | -88.88M |
| EBITDA | 12.81M |
| EBIT | -2.54M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
The company has 104.71M in cash and 12.82M in debt, giving a net cash position of 91.89M.
| Cash & Cash Equivalents | 104.71M |
| Total Debt | 12.82M |
| Net Cash | 91.89M |
| Retained Earnings | -1.77B |
| Total Assets | 490.42M |
| Working Capital | 261.58M |
Cash Flow
In the last 12 months, operating cash flow was -52.02M and capital expenditures 0, giving a free cash flow of -52.02M.
| Operating Cash Flow | -52.02M |
| Capital Expenditures | 0 |
| Free Cash Flow | -52.02M |
| FCF Per Share | -0.25 |
Margins
Gross margin is 97.28%, with operating and profit margins of -0.56% and -19.72%.
| Gross Margin | 97.28% |
| Operating Margin | -0.56% |
| Pretax Margin | -19.29% |
| Profit Margin | -19.72% |
| EBITDA Margin | 2.84% |
| EBIT Margin | -0.56% |
| FCF Margin | -11.54% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5% |
| FCF Yield | -2.89% |
Analyst Forecast
The average price target for BCRX is $13.5, which is 57% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.5 |
| Price Target Difference | 57% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -2.69 |
| Piotroski F-Score | 2 |